加拿大安大略省产前抗风湿药物使用的真实世界趋势:横断面时间序列分析
该研究基于加拿大安大略省2006至2021年分娩的5256例风湿病患者,分析孕前和产前改善病情抗风湿药(DMARD)使用趋势。结果显示孕前生物制剂DMARD使用从8.3增至32.8/100 eligible population(P=0.004),产前DMARD使用上升5.7%(P=0.02),其中生物制剂DMARD从3.6增至31.3/100 eligible population(P<0.001),产前DMARD使用者比例从26.3%增至45.2%(P=0.01)。
要点
- 孕前生物制剂DMARD使用显著增加,从8.3增至32.8/100 eligible population。
- 产前DMARD使用上升5.7%,生物制剂DMARD使用增幅达775.0%。
- 产前使用DMARD者比例从26.3%升至45.2%,单药和≥2种DMARD比例亦上升。
核心结论
- 产前抗风湿药物使用增加,尤其是生物制剂DMARD,反映治疗实践演变以优化疾病控制和妊娠结局。
研究设计与样本
- 基于加拿大安大略省重复横断面数据的时间序列分析,纳入2006年4月1日至2021年3月31日分娩且享有安大略省药物福利计划(ODB)覆盖的孕妇。
- 队列包含5256例孕妇,其中576例孕前和697例产前为ODB受益人,疾病包括类风湿关节炎、系统性红斑狼疮、银屑病关节炎和/或中轴型脊柱关节炎。
主要发现
- 孕前DMARD使用相对稳定,但生物制剂DMARD使用从2006至2020财年每100 eligible population由8.3增至32.8(P=0.004)。
- 产前DMARD使用上升5.7%(P=0.02),生物制剂DMARD从每100 eligible population 3.6增至31.3(P<0.001)。
- 年度队列中产前使用DMARD者比例从26.3%增至45.2%(P=0.01)。
- 使用DMARD者中,2019年单药DMARD比例升至32.9%,≥2种DMARD比例升至12.3%(P=0.02)。
临床怎么用
- 临床实践中应关注风湿病孕妇产前抗风湿药物使用增加的趋势,尤其是生物制剂DMARD的广泛应用。
- 治疗决策需平衡疾病控制与妊娠安全,反映不断演变的治疗实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aimed to describe real-world trends in preconception and prenatal use of antirheumatic drugs among pregnant individuals with rheumatic diseases in Ontario, Canada. METHODS: We conducted a time-series analysis using repeated cross-sectional data to examine annual patterns of disease-modifying antirheumatic drug (DMARD) use among pregnant individuals with rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, and/or axial spondyloarthritis. The study included those with Ontario Drug Benefit Program (ODB) coverage who delivered between April 1, 2006, and March 31, 2021. For calendar years 2007, 2011, 2015, and 2019, we described demographic, clinical, and DMARD use characteristics among ODB beneficiaries. RESULTS: The cohort included 5,256 pregnant individuals, with 576 preconception and 697 prenatal ODB beneficiaries. Preconception DMARD use remained relatively stable, but biologic DMARD use increased by 293.1%, from 8.3 to 32.8 users per 100 eligible population from fiscal years 2006 to 2020 (P = 0.004). Prenatal DMARD use rose by 5.7% (P = 0.02), with biologic DMARD use increasing by 775.0%, from 3.6 to 31.3 users per 100 eligible population (P < 0.001). Across the annual cohorts, the proportion of those who used DMARDs prenatally nearly doubled from 26.3% to 45.2% (P = 0.01). Among those who used DMARDs, the proportion receiving a single DMARD rose to 32.9% in 2019, and the proportion receiving two or more DMARDs also rose to 12.3% (P = 0.02). CONCLUSION: Prenatal antirheumatic drug use has increased, particularly for biologic DMARDs. These trends reflect evolving treatment practices aimed at optimizing disease control and pregnancy outcomes for individuals with rheumatic diseases.
引用
- Tharmarajah S, Hussain S, Guilcher SJT, et al. Real-World Trends in Prenatal Antirheumatic Drug Utilization in Ontario, Canada: A Cross-Sectional Time-Series Analysis. Arthritis Care Res (Hoboken). 2026. PMID: 42047342. doi:10.1002/acr.80079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。